These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

228 related items for PubMed ID: 6223205

  • 1. Interactions of ergot alkaloids with anterior pituitary D-2 dopamine receptors.
    Sibley DR, Creese I.
    Mol Pharmacol; 1983 May; 23(3):585-93. PubMed ID: 6223205
    [Abstract] [Full Text] [Related]

  • 2. Interactions of dopaminergic agonists and antagonists with dopaminergic D3 binding sites in rat striatum. Evidence that [3H]dopamine can label a high affinity agonist-binding state of the D1 dopamine receptor.
    Leff SE, Creese I.
    Mol Pharmacol; 1985 Feb; 27(2):184-92. PubMed ID: 3969067
    [Abstract] [Full Text] [Related]

  • 3. Correlation of alpha- and beta-rotameric forms of 2-substituted octahydrobenzo[f]quinoline dopamine congeners with high and low affinity states of the anterior pituitary dopamine receptor and prolactin inhibition.
    Findell PR, Torkelson SM, Craig JC, Weiner RI.
    Mol Pharmacol; 1988 Jan; 33(1):78-83. PubMed ID: 3336350
    [Abstract] [Full Text] [Related]

  • 4. Anterior pituitary dopamine receptors. Demonstration of interconvertible high and low affinity states of the D-2 dopamine receptor.
    Sibley DR, De Lean A, Creese I.
    J Biol Chem; 1982 Jun 10; 257(11):6351-61. PubMed ID: 6176582
    [Abstract] [Full Text] [Related]

  • 5. Guanine nucleotides reveal differential actions of ergot derivatives at D-2 receptors labelled by [3H]spiperone in striatal homogenates.
    Gundlach AL, Krstich M, Beart PM.
    Brain Res; 1983 Nov 14; 278(1-2):155-63. PubMed ID: 6227373
    [Abstract] [Full Text] [Related]

  • 6. The ternary complex model. Its properties and application to ligand interactions with the D2-dopamine receptor of the anterior pituitary gland.
    Wreggett KA, De Léan A.
    Mol Pharmacol; 1984 Sep 14; 26(2):214-27. PubMed ID: 6237254
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Dopaminergic activity of some ergot alkaloid derivatives: relationship to their chemical structure.
    Soskić V, Petrović J, Trajković D, Kidric M.
    Pharmacology; 1986 Sep 14; 32(3):157-66. PubMed ID: 2938196
    [Abstract] [Full Text] [Related]

  • 9. Chronic estrogen treatment promotes a functional uncoupling of the D2 dopamine receptor in rat anterior pituitary gland.
    Munemura M, Agui T, Sibley DR.
    Endocrinology; 1989 Jan 14; 124(1):346-55. PubMed ID: 2521206
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Phenoxybenzamine treatment differentiates dopaminergic 3H-ligand binding sites in bovine caudate membranes.
    Hamblin MW, Creese I.
    Mol Pharmacol; 1982 Jan 14; 21(1):44-51. PubMed ID: 6127621
    [Abstract] [Full Text] [Related]

  • 12. Characterization of D-2 dopamine receptors in a tumor of the rat anterior pituitary gland.
    Lin C, McGonigle P, Molinoff PB.
    J Pharmacol Exp Ther; 1987 Sep 14; 242(3):950-6. PubMed ID: 2958621
    [Abstract] [Full Text] [Related]

  • 13. Interactions of dopamine agonists with brain D1 receptors labeled by 3H-antagonists. Evidence for the presence of high and low affinity agonist-binding states.
    Leff SE, Hamblin MW, Creese I.
    Mol Pharmacol; 1985 Feb 14; 27(2):171-83. PubMed ID: 3969066
    [Abstract] [Full Text] [Related]

  • 14. Distinctions between ligand-binding sites for [3H]dopamine and D2 dopaminergic receptors characterized with [3H]spiroperidol.
    Hancock AA, Marsh CL.
    Mol Pharmacol; 1984 Nov 14; 26(3):439-51. PubMed ID: 6238230
    [Abstract] [Full Text] [Related]

  • 15. Dopamine D2 receptors in the anterior pituitary: a single population without reciprocal antagonist/agonist states.
    George SR, Watanabe M, Seeman P.
    J Neurochem; 1985 Apr 14; 44(4):1168-77. PubMed ID: 2579204
    [Abstract] [Full Text] [Related]

  • 16. [35S]Guanosine-5'-O-(3-thio)triphosphate binding as a measure of efficacy at human recombinant dopamine D4.4 receptors: actions of antiparkinsonian and antipsychotic agents.
    Newman-Tancredi A, Audinot V, Chaput C, Verrièle L, Millan MJ.
    J Pharmacol Exp Ther; 1997 Jul 14; 282(1):181-91. PubMed ID: 9223553
    [Abstract] [Full Text] [Related]

  • 17. D-2 dopamine receptors in aging mouse striatum: determination of high- and low-affinity agonist binding sites.
    Severson JA, Randall PK.
    J Pharmacol Exp Ther; 1985 May 14; 233(2):361-8. PubMed ID: 3158731
    [Abstract] [Full Text] [Related]

  • 18. Agonist interactions with dopamine receptors: focus on radioligand-binding studies.
    Creese I, Sibley DR, Leff SE.
    Fed Proc; 1984 Oct 14; 43(13):2779-84. PubMed ID: 6383871
    [Abstract] [Full Text] [Related]

  • 19. Binding interactions of ergot alkaloids with monoaminergic receptors in the brain.
    Goldstein M, Lew JY, Hata F, Lieberman A.
    Gerontology; 1978 Oct 14; 24 Suppl 1():76-85. PubMed ID: 22480
    [Abstract] [Full Text] [Related]

  • 20. Bromocriptine, a dopamine D(2) receptor agonist with the structure of the amino acid ergot alkaloids, induces neurite outgrowth in PC12 cells.
    Oda T, Kume T, Izumi Y, Takada-Takatori Y, Niidome T, Akaike A.
    Eur J Pharmacol; 2008 Nov 19; 598(1-3):27-31. PubMed ID: 18835264
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.